KemPharm, Inc. (KMPH)
(Delayed Data from NSDQ)
$1.37 USD
+0.06 (4.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
+0.06 (4.58%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
by Zacks Equity Research
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
by Zacks Equity Research
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Cronos Group (CRON) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 0% and 7.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
KemPharm (KMPH) Starts Early-Stage Cardiovascular Safety Study
by Zacks Equity Research
KemPharm (KMPH) initiates dosing in a phase I study to evaluate the cardiovascular safety profile of its lead pipeline candidate, KP1077's sole active API, serdexmethylphenidate.
Implied Volatility Surging for KemPharm (KMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
Implied Volatility Surging for KemPharm (KMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in KemPharm (KMPH) Stock?
by Radhika Saraogi
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
KemPharma (KMPH) Moves 42.8% Higher: Will This Strength Last?
by Zacks Equity Research
KemPharma (KMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys
by Zacks Equity Research
The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.
Do Options Traders Know Something About KemPharm (KMPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty
by Kinjel Shah
There is uncertainty about the impact of the coronavirus pandemic on the Zacks Medical-Drugs industry. However, with demand trends expected to improve in the second half of 2020, SAVA, KMPH, NERV, ALDX may prove to be good additions to the portfolio.
KemPharma (KMPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
KemPharma (KMPH) delivered earnings and revenue surprises of -1100.00% and -63.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
KemPharma (KMPH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
KemPharma (KMPH) delivered earnings and revenue surprises of -28.57% and -62.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ArQule (ARQL) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
ArQule (ARQL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Implied Volatility Surging for KemPharm (KMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
KemPharm Posts Positive Top-Line Results on KP415 Prodrug
by Zacks Equity Research
KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.
Options Traders Expect Huge Moves in KemPharm (KMPH) Stock
by Zacks Equity Research
Investors in KemPharm (KMPH) need to pay close attention to the stock based on moves in the options market lately.
KemPharm Stock Down Despite Positive Data on ADHD Candidate
by Zacks Equity Research
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
KemPharm (KMPH) Shares March Higher, Can It Continue?
by Zacks Equity Research
KemPharm, Inc. (KMPH) has been on the move lately as the stock has risen by 45.4% in the past four weeks, and it is currently trading well above its 20-Day SMA
KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline
by Zacks Equity Research
KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.